Navigation Links
Xytis Names Gordon H. Busenbark as Chief Financial Officer
Date:10/19/2007

IRVINE, Calif., Oct. 19 /PRNewswire/ -- Xytis Inc., a privately held biotechnology company focused on developing novel therapeutics to treat central nervous system (CNS) diseases, today announced that Gordon H. Busenbark has joined the company as Chief Financial Officer. Mr. Busenbark has more than 25 years of experience in the pharmaceutical, biotechnology and medical devices industries. During a 23 year career at Baxter Healthcare, Mr. Busenbark held a number of senior-level financial, operational and general management positions in both the U.S. and Europe. This included roles as Chief Financial Officer of Immuno AG when the company was acquired by Baxter, and President of Baxter's global Plasma Therapeutics business. Mr. Busenbark's most recent role was as Chief Financial Officer at Encysive Pharmaceuticals, where his accomplishments included raising more than $100 million in debt and equity financing.

"We are very pleased to have Gordon join Xytis," said Vincent F. Simmon, CEO and President. "He brings great financial and operational experience, both from a large pharmaceutical company perspective as well as from that of a smaller biotechnology company. Gordon joins us at an exciting time for Xytis. Our Phase 2 clinical trial in Traumatic Brain Injury (TBI) is approximately half way enrolled. Also, there is considerable partnering interest in two of our pre-clinical programs; positive allosteric modulators of GABA-A receptor and of alpha-7 nicotinic acetylcholine receptors. His experience and assistance in financing and marshalling these programs forward will be greatly welcomed."

Mr. Busenbark has both a B.S. in Accounting and an MBA from the University of Utah.

About Xytis

Xytis Inc. is a privately held discovery and development biopharmaceutical company, headquartered in Irvine, California, and having a clinical development group in Nyon, Switzerland, focused on innovative CNS drug candidates. The Company's investors include At
'/>"/>

SOURCE Xytis Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 The National Necrotizing Fasciitis Foundation ... has been successfully treated for a life threatening form ... Anibal R. Gauto , Medical Director of Inpatient Wound Care ... Center in Rancho Mirage, California . ... Dr. John Crew at Seton Hospital in ...
(Date:8/20/2014)... , Aug. 20, 2014 Research and Markets ... of Pralmorelin" report to their offering. ... comprehensive data on Pralmorelin globally and regionally ( Europe ... America , Latin America etc.). ... This report focuses on three primary areas; manufacture ...
(Date:8/20/2014)... Research and Markets has ... Wound Care and Closure Market (Types, Applications, End ... Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, ... to their offering. The new ... market (types, applications, end user and geography) - ...
Breaking Medicine Technology:Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 2Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 3Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 4Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 5Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 6Global Market Report of Pralmorelin 2Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2
(Date:8/20/2014)... Reinberg HealthDay Reporter WEDNESDAY, ... cancer cells grow may help doctors diagnose and treat the ... investigators have found that the deadliest skin cancers occur most ... a long history of sun exposure. These lesions also ... Rapid cell growth -- called "high mitotic rate" -- ...
(Date:8/20/2014)... common approach to treating kidney failure by removing waste ... for people who suddenly developed the condition, in an ... School of Medicine. , Their findings, published online in ... an aggressive method that is standardly used for people ... benefit to the patient. , "Our findings question the ...
(Date:8/20/2014)... NEW YORK, NY (August 20, 2014) Research from ... a critical role in stomach cancer growth and that ... be an effective treatment for the disease. The study ... MD, in collaboration with Duan Chen, MD, PhD, in ... Science Translational Medicine . , "Scientists have long observed ...
(Date:8/20/2014)... 20, 2014 The non-small cell lung ... in the offing across the top 8 developed nations, ... to around USD 8 billion by 2020-end, posting a ... is projected to be driven by innovative therapies entering ... lacking efficient treatment, unlike the non-squamous segment. Thus, patients ...
(Date:8/20/2014)... CA (PRWEB) August 20, 2014 The main ... 12 per diode panel band perfect spectrum that encompasses the ... most likely to use during photosynthesis. A key point ... is that they almost exclusively reside between 440-480 on the ... the red side of the spectrum. The KIND LED K3 ...
Breaking Medicine News(10 mins):Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 3Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 4Health News:Cheap LED Grow Lights Are Quickly Being Replaced by Premium Grow Lights 2
... ... 18 million Americans suffer from heavy snoring, but don’t realize it,s likely a tell-tale sign ... ... Americans suffer from heavy snoring, but don’t realize it may actually be a tell-tale sign ...
... 16 The 15th Annual National Ergonomics Conference ... - 20, will focus on the importance of workplace ergonomics ... topics of return on investment, the aging workforce, and safety ... offices and call centers, industrial, lab, healthcare, and uncontrolled environments ...
... It was found less effective than extended-release niacin, or ... new study raises more questions about ezetimibe (Zetia), a ... statins to lower LDL, or "bad," cholesterol. , The ... June after it was discovered that LDL-cholesterol-lowering Zetia was ...
... modern medicine finds a way to treat a medical condition, ... also have to find ways to get that treatment into ... research from North Carolina State University shows that much more ... hemophilia patients in the developing world, and that the current ...
... SINGAPORE, Nov. 16 /PRNewswire-Asia/ -- Retail sales ... in the first half of 2009 with,total consumption peaking in ... Contact Lens manufacturers. Positive sales,data showing a growth of 14% ... economic recovery that is being led by consumers spending. , ...
... of ketamine users has been published online today in ... Special K) use increasing faster than any other drug ... showing the consequences of repeated ketamine use provides valuable ... the study, researchers from University College London followed 150 ...
Cached Medicine News:Health News:Heavy Snoring Linked To Potentially Life-Threatening Conditions 2Health News:Heavy Snoring Linked To Potentially Life-Threatening Conditions 3Health News:2009 National Ergonomics Conference Opens in Las Vegas November 17 With Hundreds of Industry Leaders in Attendance 2Health News:Study Raises New Questions About Cholesterol Drug Zetia 2Health News:Study Raises New Questions About Cholesterol Drug Zetia 3Health News:Research highlights need to address hemophilia in developing world 2Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 2Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 3Health News:First ever large-scale study of ketamine users published 2
... UltraClean Agarose, Molecular Biology Grade, ... separation of nucleic acids. It ... DNA fragments from 0.2 to ... UltraClean Agarose is tested and ...
Inquire...
... Agarose 1000 is specifically formulated for high ... fragments <1000 bp. This standard melting temperature ... little as 10 bp difference in size. ... strong gel structure for better handling and ...
High EEO (-mr) (0.23-0.26), suitable for IEP, Gel point (1.5%): 36 1.5 °C Gel strength (1%): > 750 g/cm2....
Medicine Products: